ONCY: the cash flow

MyFinsight

Cash Flow	2026-06-30	2026-03-31	2025-12-31
Net loss	-9,442	-9,243	-28,759
Depreciation of property and equipment	15	16	70
Non-cash lease expense	71	73	288
Stock-based compensation expense	1,788	2,299	3,104
Value of shares issued to consultants	657	730	3,467
Unrealized foreign exchange loss	-7	-13	137
Change in fair value of warrant derivative	0	0	-153
Fair value loss from sepa arrangement	0	-	-388
Value of shares issued for sepa arrangement commitment fees	0	-	440
Other receivables	253	388	-3
Prepaid expenses	742	155	-580
Accounts payable	730	-813	2,932
Accrued liabilities	-894	249	-360
Pancreatic cancer action network (pancan) receivables and payables	-	-	-1,682
Operating lease liabilities	-75	-74	-293
Net cash used in operating activities	-8,138	-7,293	-20,112
Acquisition of property and equipment	0	6	6
Net cash used in investing activities	0	-6	-6
Proceeds from exercise of warrant derivative	-	-	0
Proceeds from issuance of common stock-At The Market Offering Agreement	14,385	-	11,767
Proceeds from issuance of common stock-Standby Equity Purchase Agreement	0	-	2,348
Proceeds from stock option exercise	-	-	32
Other	-	-	-27
Proceeds from at-the-market offering agreements, net of issuance costs	-	7,614	-
Net cash provided by financing activities	6,771	7,614	14,120
Effect of exchange rate changes on cash and cash equivalents	-11	-24	121
Net decrease in cash and cash equivalents	-1,378	291	-5,877
Cash and cash equivalents, beginning of period	5,493	5,202	11,079
Cash and cash equivalents, end of period	4,115	5,493	5,202

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.